RYAH Group (CSE: RYAH) develops innovative IoT products that capture powerful data insights and is on a mission to transform patient care using big data and AI to reshape the understanding and uses of plant-based medicines. The company’s devices and data are being used by a rapidly growing number of participants in plant-based clinical trials around the world, including clinical research into the relationship between medical cannabis consumption and cancer treatment, which is in the very early stages. “Two key constraints that have limited the viability of cannabis studies within an oncological setting are the highly variable nature of the cannabis plant and traditional methods of cannabis consumption that make patient intake challenging to measure,” explains a recent article. “The RYAH Group intends to resolve this issue with the launch of their proprietary RYAH Smart Dry Herb Inhaler. The product is the first dry-herb inhaler that tracks and controls how much is inhaled, providing consistent and predictable results. The inhaler connects with the RYAH Health App… Moreover, the device also permits a post-session review mechanism that collects session data, an essential requirement for any clinical study.”
To view the full article, visit https://ibn.fm/8AtfU
About RYAH Group Inc.
RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information, visit www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork